bluebird bio (BLUE) Misses Q2 EPS by 39c

bluebird bio (NASDAQ: BLUE) reported Q2 EPS of ($3.58), $0.39 worse than the analyst estimate of ($3.19). Revenue for the quarter came in at $7.47 million versus the consensus estimate of $19.68 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS cuts KOSPI target by nearly 10% to reflect higher rates
• Barclays says AI trade is maturing, favors greater diversification